Skandinaviska Enskilda Banken AB publ Increases Position in Teva Pharmaceutical Industries Ltd. $TEVA

Skandinaviska Enskilda Banken AB publ grew its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 3.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,801,001 shares of the company’s stock after purchasing an additional 53,100 shares during the period. Skandinaviska Enskilda Banken AB publ owned approximately 0.16% of Teva Pharmaceutical Industries worth $36,380,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Advisors Asset Management Inc. purchased a new position in Teva Pharmaceutical Industries during the second quarter valued at $41,000. Cromwell Holdings LLC raised its position in shares of Teva Pharmaceutical Industries by 40.3% in the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after purchasing an additional 629 shares during the last quarter. MAI Capital Management raised its position in shares of Teva Pharmaceutical Industries by 26.8% in the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after purchasing an additional 697 shares during the last quarter. LRI Investments LLC boosted its stake in Teva Pharmaceutical Industries by 246.0% in the 3rd quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock worth $57,000 after purchasing an additional 2,000 shares in the last quarter. Finally, JTC Employer Solutions Trustee Ltd purchased a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at about $65,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 1.2%

Shares of TEVA stock opened at $34.40 on Wednesday. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $37.35. The firm has a fifty day moving average price of $32.31 and a 200-day moving average price of $24.81. The company has a market cap of $39.46 billion, a price-to-earnings ratio of 28.67, a PEG ratio of 1.94 and a beta of 0.70. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The business had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. During the same quarter in the previous year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries’s revenue for the quarter was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, equities analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insider Activity

In related news, VP Richard Daniell sold 115,468 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the transaction, the vice president owned 48,384 shares in the company, valued at approximately $1,387,653.12. The trade was a 70.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Roberto Mignone sold 77,400 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total value of $2,340,576.00. Following the completion of the sale, the director owned 367,600 shares of the company’s stock, valued at $11,116,224. The trade was a 17.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 422,060 shares of company stock worth $12,254,965 in the last quarter. 0.49% of the stock is currently owned by insiders.

Analyst Ratings Changes

TEVA has been the topic of several analyst reports. Bank of America upped their target price on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Jefferies Financial Group lifted their target price on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Finally, Truist Financial upped their price target on Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, January 29th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.11.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.